A Phase IIa/IIb Clinical Study of SHR-A1904 in Patients With Previous Systemic Treatment Failure, Positive CLDN18.2 Expression of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Latest Information Update: 07 Apr 2026
At a glance
- Drugs SHR-A1904 (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 31 Mar 2026 Status changed from not yet recruiting to recruiting.
- 10 Mar 2026 New trial record